Glucagon-like peptide-1 receptor agonists (GLP-1RAs), beyond their glucoregulatory and weight-loss benefits, exhibit potential cardioprotective effects that may be relevant to AF. This evidence concerns the gene GLP1R and atrial fibrillation.